DTG/RPV dolutegravir/rilpivirine

Recommended as continuation therapy for people with undetectable HIV viral load for at least 6 months and do not have HBV co-infection.
Single-Tablet Regimen

Standard Dose

One tablet once daily, with a meal (see Edurant), for adults who are virologically suppressed (have an undetectable viral load of less than 50 copies per mL) on a current ART (antiretroviral therapy) regimen for at least six months and who have no history of treatment failure or resistance mutations associated with rilpivirine or dolutegravir. Tablet contains 50 mg of the INSTI dolutegravir plus 25 mg of the NNRTI rilpivirine.

Take missed dose as soon as possible, with a meal, unless it is closer to the time of your next dose. Do not double up on your next dose. For proper absorption, rilpivirine must be taken with a meal that you chew—not just nutritional drinks or protein shakes.
  • See the individual drugs contained in Juluca: Tivicay and Edurant.
  • See package insert for more complete information on potential side effects and interactions.


ViiV Healthcare
viivhealthcare.com; juluca.com
(877) 844-8872



Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments